Amdocs Ltd

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Thu, Jan. 28, 12:23 PM
    • BofA/Merrill has upgraded Amdocs (DOX +2.8%) to Buy ahead of its Feb. 2 FQ1 report, and set a $63 target.
    • Shares have rallied above $53. Amdocs currently goes for 14x an FY17 (ends Sep. '17) EPS consensus of $3.84.
    • Two months ago: Amdocs falls after mixed results, soft guidance, dividend hike
    | Thu, Jan. 28, 12:23 PM
  • Nov. 11, 2015, 12:53 PM
    • In addition to missing FQ4 revenue estimates (while beating on EPS), Amdocs (NASDAQ:DOX) is guiding for FQ1 revenue of $905M-$945M and EPS of $0.82-$0.88, below a consensus of $953.4M and $0.90. The outlook is said to reflect "expectations regarding macro and industry specific risks and various uncertainties resulting from current and potential customer consolidation activity in North America."
    • Also: Amdocs is guiding for FY16 (ends Sep. '16) EPS growth of 3.5%-7.5%. That implies a range of $3.50-$3.63, below a $3.67 consensus. CEO Eli Gelman: "This outlook takes into consideration many macro and industry specific risks and unknowns, including uncertainties related to AT&T's discretionary spending plans..."
    • Along with the numbers, Amdocs states it's hiking its quarterly dividend by $0.025 to $0.195/share, provided shareholders approve at the February annual meeting. At current levels, the new dividend would spell a 1.4% yield.
    • Gelman insists the telecom customer support/billing software firm's win rate remained strong across all regions in FY15. Major deals were struck in FQ4 with Vodafone UK, KT, Singtel, and Bell Canada. 12-month backlog rose by $70M Q/Q and $80M Y/Y to $3.08B.
    • FQ4 details: Weak North American sales weighed on results: They fell 5% Y/Y to $626.6M. With the help of the Comverse deal, European sales rose 9% to $115.3M, and rest of world sales 40% to $184.9M. Costs/expenses rose 3% Y/Y to $769.9M (even with revenue growth). EPS was lifted by $182M worth of buybacks. Amdocs ended FQ4 with $1.35B in cash, and $220M in short-term financing arrangements.
    • Peer CSG Systems (NASDAQ:CSGS) is following Amdocs lower.
    • Amdocs' FQ4 results, PR
    | Nov. 11, 2015, 12:53 PM
  • Apr. 21, 2015, 3:39 PM
    • Israel's Globes reports Comverse (CNSI +6.8%) is in advanced talks to sell its billing services ops to Amdocs (DOX +0.9%) for $300M-$400M.
    • The report follows a deal between Comverse and Indian outsourcing firm Tech Mahindra that involves the transfer of hundreds of employees from Comverse's Digital Services unit.
    • Comverse has spiked higher on the report; shares jumped 5 days ago following a Q1 beat. JPMorgan argues a deal would make strategic/financial sense for Amdocs, but reiterates a Neutral rating.
    | Apr. 21, 2015, 3:39 PM
  • Jan. 30, 2014, 9:52 AM
    • Vipshop (VIPS -4%) has been cut to Neutral by UBS. Bof/A/Merrill and UBS started shares at Buy earlier this month.
    • Sequans (SQNS +3.6%) has been upgraded to Outperform by Baird ahead of its Feb. 6 Q4 report.
    • Amdocs (DOX +3.9%) has been upgraded to Outperform by Oppenheimer following yesterday afternoon's FQ1 beat.
    • PTC (PTC +3.7%) has been upgraded to Overweight by JPMorgan. The company posted an FQ1 beat a week ago.
    • Blackbaud (BLKB -1.4%) has been cut to Underweight by JPMorgan.
    • Integrated Silicon (ISSI -2.8%) has been cut to Hold by Craig-Hallum a day after posting mixed FQ1 results.
    • Synopsys (SNPS +0.2%) and SS&C (SSNC -3.6%) have been cut to Neutral by JPMorgan.
    • Spansion (CODE +1.9%) has been started at Overweight by Morgan Stanley ahead of its Feb. 4 Q4 report.
    | Jan. 30, 2014, 9:52 AM
Company Description
Amdocs Ltd is a provider of software products and services to the communications, media and entertainment industry. It provides software and services solutions in North America and Europe.